CancerVax Expands Research on AI-Driven Liver Cancer Detection

Lehi, Utah – June 9, 2025 – CancerVax, Inc., a pioneering biotechnology firm recognized for its innovative universal cancer treatment platform, has announced a significant expansion of its preclinical program to include rare liver cancers, specifically hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). This initiative utilizes artificial intelligence (AI) and machine learning technologies to identify distinct biomarkers associated with these aggressive cancer types, which exhibit stem cell characteristics and are known for their poor prognosis.

The innovative approach of CancerVax employs engineered lipid nanoparticles designed to accurately detect and target cancer cells while sparing healthy tissue. According to Dr. Adam Grant, Principal Scientist at CancerVax, the identification of a unique Marker2 signature specific to these rare liver cancers presents a promising avenue for addressing a significant unmet clinical need. "When we first identified these subsets of liver cancers with this distinct Marker2 signature, I couldn’t believe it. It was amazing to come across a patient population that has a high unmet clinical need and is uniquely suited to validate our technology," Dr. Grant stated.

CancerVax's platform is built on a two-step detection mechanism. Initially, the nanoparticles target cancer cells with specific surface proteins identified as Marker1. Following this, proprietary Smart mRNAs are released only in the presence of cancer-specific signatures, referred to as Marker2. Once activated, the mRNA prompts cancer cells to express proteins associated with well-immunized diseases, such as measles, thus tricking the immune system into attacking these cancer cells as if they were pathogens. This innovative strategy underscores the adaptability of CancerVax’s treatment modalities, which are designed to be customizable for various cancer types.

Dr. George Katibah, Chief Scientific Officer at CancerVax, noted the striking results from their AI-driven analysis, emphasizing that the underlying biology of these tumors can be effectively targeted using their novel approach. "This particular cancer biology leads to not one but a group of rare liver cancers for which there are limited treatments. Our team has uncovered this novel cancer stem cell biology using advanced computational techniques showing that these tumors’ underlying biology can be targeted by the CancerVax approach," he explained.

Historically, liver cancer has posed significant treatment challenges, especially in cases involving stem cell-like properties. According to the American Cancer Society, liver cancer incidence has been rising, with HCC being the most common subtype. The prognosis for patients diagnosed with advanced liver cancer remains grim, with a five-year survival rate of less than 20% (American Cancer Society, 2023).

The expansion to include these liver cancer types adds to CancerVax's existing focus on pancreatic ductal adenocarcinoma (PDAC), further establishing the company's commitment to addressing cancers with high mortality rates. This strategic direction not only enhances the universality of CancerVax’s platform but also aligns with a growing trend in cancer treatment that emphasizes precision medicine and immunotherapy.

Looking ahead, CancerVax aims to create new nanoparticles tailored for these liver cancer indications and will conduct comprehensive in vitro and in vivo studies to evaluate the efficacy and safety of their treatments. The company’s universal cancer treatment platform is structured to facilitate rapid development of off-the-shelf immunotherapies, akin to flu shots, thereby increasing accessibility for patients in need.

As cancer research continues to evolve, CancerVax represents a beacon of hope for patients battling some of the most aggressive and treatment-resistant forms of the disease. With its innovative approach, CancerVax is poised to make significant strides toward enhancing survival rates and improving the quality of life for cancer patients worldwide.

For further information, visit www.CancerVax.com.

**Forward-Looking Statements**: This press release may contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance and are subject to risks and uncertainties. CancerVax undertakes no obligation to publicly update any forward-looking statements made herein.